OS outcomes by receipt of treatment between White and Black patients with MM
| Study (author, year) . | Study setting . | Treatment . | Black vs White HR (95% CI) . | Variables adjusted for . |
|---|---|---|---|---|
| SCT | ||||
| Kaur et al20 (2021) | Single center | SCT + induction and systemic therapy | 0.32 (0.07-1.37) | Race, age, risk classification, gender, type and response to induction therapy, and transplant utilization |
| Badar et al55 (2020) | Multicenter | SCT + induction/maintenance systemic therapy | 0.53 (0.30-0.93) | Age at transplant, time to transplant, maintenance therapy after transplant, stage at diagnosis, gender, SCT, and comorbidity index |
| Ailawadhi et al78 (2020) | Multicenter | SCT + induction/maintenance and systemic therapy | 0.56 (0.35-0.89) | Age group, history of asymptomatic disease, amyloidosis, family history of other cancers, sex, calcium, hemoglobin, and calculated ISS stage |
| Lupak et al79 (2021) | Single center | SCT + induction chemotherapy | 0.66 (0.32-1.39) | Cytogenetics, age at diagnosis, comorbidities, induction therapies, and income |
| Scott et al74 (2016) | Multicenter | SCT + systemic therapy | 1.7 (1.1-2.5) | High-risk MM, race, ISS/Durie-Salmon stage III, pretransplant response, and planned posttransplant therapy |
| No SCT | ||||
| Ailawadhi et al78 (2020) | Multicenter | Systemic therapy | 0.86 (0.70-1.06) | Cohort, age group, history of asymptomatic myeloma, history of amyloidosis, family history of other cancers, sex, calcium, hemoglobin, and calculated ISS stage |
| Jayakrishnan et al80 (2021) | Multicenter | Systemic therapy | 0.9 (0.87-0.93) | Age, year of diagnosis, comorbidity, sex, lack of insurance or Medicaid insurance, income, facility center type (academic and community), and education |
| Kaur et al20 (2021) | Single center | Systemic therapy | 0.83 (0.42-1.75) | Race, age, IMWG risk classification, gender, type and response to induction therapy, and SCT utilization |
| Mixed treatment (SCT and/or systemic therapy) | ||||
| Kaur et al20 (2021) | Single center | Systemic therapy and transplant | 0.83 (0.42-1.75) | Race, age, IMWG risk classification, gender, type and response to induction therapy, and SCT utilization |
| Fiala and Wildes8 (2017) | Multicenter | Systemic therapy and transplant | 0.91 (0.85-0.97) | Demographics (race, sex, year of diagnosis), treatment (SCT and bortezomib use), overall health measures, and potential access barriers |
| 1.05 (0.99-1.12) | Race, sex, year of diagnosis, and SCT and bortezomib use | |||
| 1.12 (1.05-1.19) | Race, sex, and year of diagnosis | |||
| Fillmore et al81 (2018) | Multicenter | Systemic therapy and transplant | 0.79 (0.72-0.87) | Age, SCT, use of novel therapy, and disease stage |
| Ailawadhi et al73 (2017) | Multicenter | Systemic therapy and transplant | 1.11 (1.01-1.22) | Age, sex, rurality, income, stage, and transplantation |
| Makhani et al82 (2021) | Multicenter | Not reported | 0.91 (0.85-0.98) | Age, sex, ethnicity, marital status, and area of residence |
| Costa et al83 (2016) | Multicenter | Not reported | 1.01 (0.91-1.11) | Age, sex, insurance, education, income, marital status, and demographic area |
| Study (author, year) . | Study setting . | Treatment . | Black vs White HR (95% CI) . | Variables adjusted for . |
|---|---|---|---|---|
| SCT | ||||
| Kaur et al20 (2021) | Single center | SCT + induction and systemic therapy | 0.32 (0.07-1.37) | Race, age, risk classification, gender, type and response to induction therapy, and transplant utilization |
| Badar et al55 (2020) | Multicenter | SCT + induction/maintenance systemic therapy | 0.53 (0.30-0.93) | Age at transplant, time to transplant, maintenance therapy after transplant, stage at diagnosis, gender, SCT, and comorbidity index |
| Ailawadhi et al78 (2020) | Multicenter | SCT + induction/maintenance and systemic therapy | 0.56 (0.35-0.89) | Age group, history of asymptomatic disease, amyloidosis, family history of other cancers, sex, calcium, hemoglobin, and calculated ISS stage |
| Lupak et al79 (2021) | Single center | SCT + induction chemotherapy | 0.66 (0.32-1.39) | Cytogenetics, age at diagnosis, comorbidities, induction therapies, and income |
| Scott et al74 (2016) | Multicenter | SCT + systemic therapy | 1.7 (1.1-2.5) | High-risk MM, race, ISS/Durie-Salmon stage III, pretransplant response, and planned posttransplant therapy |
| No SCT | ||||
| Ailawadhi et al78 (2020) | Multicenter | Systemic therapy | 0.86 (0.70-1.06) | Cohort, age group, history of asymptomatic myeloma, history of amyloidosis, family history of other cancers, sex, calcium, hemoglobin, and calculated ISS stage |
| Jayakrishnan et al80 (2021) | Multicenter | Systemic therapy | 0.9 (0.87-0.93) | Age, year of diagnosis, comorbidity, sex, lack of insurance or Medicaid insurance, income, facility center type (academic and community), and education |
| Kaur et al20 (2021) | Single center | Systemic therapy | 0.83 (0.42-1.75) | Race, age, IMWG risk classification, gender, type and response to induction therapy, and SCT utilization |
| Mixed treatment (SCT and/or systemic therapy) | ||||
| Kaur et al20 (2021) | Single center | Systemic therapy and transplant | 0.83 (0.42-1.75) | Race, age, IMWG risk classification, gender, type and response to induction therapy, and SCT utilization |
| Fiala and Wildes8 (2017) | Multicenter | Systemic therapy and transplant | 0.91 (0.85-0.97) | Demographics (race, sex, year of diagnosis), treatment (SCT and bortezomib use), overall health measures, and potential access barriers |
| 1.05 (0.99-1.12) | Race, sex, year of diagnosis, and SCT and bortezomib use | |||
| 1.12 (1.05-1.19) | Race, sex, and year of diagnosis | |||
| Fillmore et al81 (2018) | Multicenter | Systemic therapy and transplant | 0.79 (0.72-0.87) | Age, SCT, use of novel therapy, and disease stage |
| Ailawadhi et al73 (2017) | Multicenter | Systemic therapy and transplant | 1.11 (1.01-1.22) | Age, sex, rurality, income, stage, and transplantation |
| Makhani et al82 (2021) | Multicenter | Not reported | 0.91 (0.85-0.98) | Age, sex, ethnicity, marital status, and area of residence |
| Costa et al83 (2016) | Multicenter | Not reported | 1.01 (0.91-1.11) | Age, sex, insurance, education, income, marital status, and demographic area |
IMWG, International Myeloma Working Group; ISS, International Staging System.